August 22, 2017
ViraCyte Announces Positive Phase 2 Trial Results
ViraCyte today announced publication of positive data from a Phase 2 clinical trial evaluating its most advanced T-cell immunotherapy product, Viralym-M. The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology.
August 17, 2017
ViraCyte Awarded $8.99M from the Cancer Prevention and Research Institute of Texas
ViraCyte today announced notification of funding approval for a Product Development Research grant totaling $8.99 million by the Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee to support the clinical development of the Company’s lead product, Viralym-M – a “ready to administer” multivirus-specific T cell immunotherapy.
July 18, 2017
ViraCyte Enters Exclusive License Agreement with Baylor College of Medicine for T Cell Immunotherapies Targeting Viruses
ViraCyte, LLC today announced that it has exercised its exclusive option with Baylor College of Medicine (Baylor) to license Baylor's virus-specific T cell therapy technology for the prevention and/or treatment of viral infections.
July 11, 2017
ViraCyte Completes Phase 1 Clinical Trial of Viralym-C
ViraCyte, LLC today announced the successful completion of a Phase I clinical trial using Viralym-C, a “ready to administer” T cell immunotherapy product for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients.
July 5, 2017
ViraCyte Awarded $3.75M from NIH and FDA to Advance T Cell Immunotherapies
ViraCyte, LLC today announced that it has been awarded $3.75M from National Institutes of Health (NIH) and the Food and Drug Administration (FDA) to advance its T cell immunotherapies.
January 24, 2017
ViraCyte Receives Orphan Drug Designation for Viralym-C
ViraCyte, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Viralym-C, a ready to administer T cell immunotherapy product for the treatment of cytomegalovirus (CMV) in severely immunocompromised patients.
January 10, 2017
ViraCyte Granted U.S. FDA Fast Track Designation for Viralym-C
ViraCyte, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Viralym-C, ViraCyte's T cell immunotherapy product designed to treat refractory cytomegalovirus (CMV) infections in patients following a stem cell transplant.
December 1, 2016
ViraCyte Announces Oral Presentations on Clinical Trial Results at the 58th American Society of Hematology Annual Meeting
ViraCyte, LLC announced today that two abstracts regarding the Company's lead product candidates, Viralym-C and Viralym-M, were selected for oral presentations at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California on December 3-6.
November 29, 2016
ViraCyte Appoints Dr. Brett Giroir as President and Chief Executive Officer
ViraCyte, LLC, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections, today announced the appointment of Brett P. Giroir, M.D. as President and Chief Executive Officer, effective immediately.
March 2, 2016
ViraCyte Selected as a Resident Company at JLABS @ TMC
Johnson & Johnson Innovation Unveils JLABS @ TMC to Help Catalyze Early Stage Research through to Commercialization for Healthcare Solutions in Houston